Donation

Tip Card: Blenrep®

Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the combination of a monoclonal antibody (mAb) that binds to a specific receptor on the surface of myeloma cells called B-cell maturation antigen (BCMA), coupled with monomethyl auristatin F (MMAF), a drug that can kill myeloma cells.

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.